[新型冠状病毒肺炎大流行期间肺癌的免疫治疗调整]

[Immunotherapy adaptation in lung cancer during the COVID-19 pandemic].

作者信息

Travert C, Cannone P, Greillier L, Tomasini P

机构信息

Aix-Marseille université, AP-HM, INSERM, CNRS, CRCM, hôpital Nord, service d'oncologie multidisciplinaire et innovations thérapeutiques, Marseille, France; Institut du cancer de Montpellier, Montpellier, France.

Aix-Marseille université, AP-HM, INSERM, CNRS, CRCM, hôpital Nord, service d'oncologie multidisciplinaire et innovations thérapeutiques, Marseille, France.

出版信息

Rev Mal Respir. 2021 Nov;38(9):865-872. doi: 10.1016/j.rmr.2021.06.005. Epub 2021 Jun 30.

DOI:10.1016/j.rmr.2021.06.005

PMID:34246519

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8241593/

Abstract

INTRODUCTION

COVID-19 pandemics required changes in medical practices. In thoracic oncology, pembrolizumab was doubled to 400mg every 6weeks, nivolumab to 480mg every 4weeks. The objective of our study was to assess the impact on quality of life, and on psychological state, as well as the tolerance, of this new schedule.

METHODS

Thoracic oncologic patients who underwent these therapeutic changes in our center during the first COVID-19 epidemic wave were included. Their quality of life was assessed using the Quality of Life Questionnaire-30, their psychological state by the Hospital Anxiety Depression (HAD) scale. We also reported the preferred administration schedule, as well as adverse events.

RESULTS

Thirty patients were included. The overall quality of life was preserved. Rates on HAD scale were low. Tolerance was acceptable. In majority, patients preferred the new procedure. They had a significantly better quality of life compared to those who preferred the old one.

CONCLUSIONS

This new immunotherapy schedule in thoracic oncology is well tolerated and allows a preservation of quality of life. This therapeutic option may be favored in the context of COVID-19 pandemics.

摘要